Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Abeona Therapeutics (ABEO) Net Margin: 2011-2025

Historic Net Margin for Abeona Therapeutics (ABEO) over the last 14 years, with Sep 2025 value amounting to -669.39%.

  • Abeona Therapeutics' Net Margin rose 3412256.00% to -669.39% in Q3 2025 from the same period last year, while for Sep 2025 it was 6,126.90%, marking a year-over-year increase of 1870104.00%. This contributed to the annual value of -167,631.58% for FY2024, which is 16608301.00% down from last year.
  • According to the latest figures from Q3 2025, Abeona Therapeutics' Net Margin is -669.39%, which was down 102.36% from 28,416.75% recorded in Q2 2025.
  • In the past 5 years, Abeona Therapeutics' Net Margin registered a high of 97,256.25% during Q4 2021, and its lowest value of -34,791.95% during Q3 2024.
  • Its 3-year average for Net Margin is 1,228.44%, with a median of -2,425.41% in 2023.
  • As far as peak fluctuations go, Abeona Therapeutics' Net Margin surged by 9,778,385bps in 2021, and later tumbled by 10,769,743bps in 2022.
  • Abeona Therapeutics' Net Margin (Quarterly) stood at 97,256.25% in 2021, then plummeted by 10,769,743bps to -10,441.18% in 2022, then surged by 782,288bps to -2,618.30% in 2023, then soared by 1,831,152bps to 15,693.22% in 2024, then surged by 3,412,256bps to -669.39% in 2025.
  • Its Net Margin was -669.39% in Q3 2025, compared to 28,416.75% in Q2 2025 and -3,846.15% in Q1 2025.